title: Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
abstract: Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70 mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in <or=6% of patients, except febrile neutropenia (15%). Cytopenias were noted in the majority of patients, and were manageable with dose interruptions/reductions. Dasatinib is associated with a promising rate of response in this high-risk population.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. jcortes@mdanderson.org
authors.forename: J
authors.initials: J
authors.lastname: Cortes
authors.forename: D-W
authors.initials: DW
authors.lastname: Kim
authors.forename: E
authors.initials: E
authors.lastname: Raffoux
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: E
authors.initials: E
authors.lastname: Ritchie
authors.forename: L
authors.initials: L
authors.lastname: Roy
authors.forename: S
authors.initials: S
authors.lastname: Coutre
authors.forename: S
authors.initials: S
authors.lastname: Corm
authors.forename: N
authors.initials: N
authors.lastname: Hamerschlak
authors.forename: J-L
authors.initials: JL
authors.lastname: Tang
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
authors.forename: H J
authors.initials: HJ
authors.lastname: Khoury
authors.forename: T H
authors.initials: TH
authors.lastname: Brümmendorf
authors.forename: M
authors.initials: M
authors.lastname: Michallet
authors.forename: G
authors.initials: G
authors.lastname: Rege-Cambrin
authors.forename: C
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: J P
authors.initials: JP
authors.lastname: Radich
authors.forename: T
authors.initials: T
authors.lastname: Ernst
authors.forename: C
authors.initials: C
authors.lastname: Zhu
authors.forename: J M A
authors.initials: JM
authors.lastname: Van Tornout
authors.forename: M
authors.initials: M
authors.lastname: Talpaz